Showing results (541-550 of 673) with videos related to
Sort By:
Pageof 68
HIV Clinical Trials|May 29, 2002
Genetic mechanisms of resistance to NRTI and NNRTIVincent Soriano, Carmen de MendozaHIV Clinical Trials|October 24, 2001
Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 studyG Carosi, F Castelli, F Suter, et al.HIV Clinical Trials|October 24, 2001
Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patientsP Chavanet, L Piroth, M Grappin, et al.HIV Clinical Trials|October 9, 2001
Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal diseaseJ A Aberg, J Watson, M Segal, et al.HIV Clinical Trials|October 9, 2001
In vivo assessment of antiviral reactivity in chronic HIV infectionK A Smith, E L Jacobson, T Sohn, et al.HIV Clinical Trials|October 9, 2001
Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot studyJ A Vazquez, J A Hidalgo, S De BonoHIV Clinical Trials|October 9, 2001
Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatmentJ A Pérez-Molina, R Pérez Nr, P Miralles, et al.HIV Clinical Trials|October 9, 2001
Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?R B Corales, N K Shrestha, A J Taege, et al.HIV Clinical Trials|October 9, 2001
Therapeutic trials in HIV infection: which benefits for which patients?L Piroth, J Y Callerot, M Grappin, et al.HIV Clinical Trials|October 9, 2001
Study of the validity of a questionnaire to assess the adherence to therapy in patients infected by HIVJ Martín, I Escobar, R Rubio, et al.Pageof 68